Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
08/2003
08/07/2003CA2473810A1 Fgfr agonists
08/06/2003EP1333094A2 Human telomerase catalytic subunit
08/06/2003EP1333088A1 Paramyxovirus vectors for introducing foreign genes into skeletal muscle
08/06/2003EP1332673A1 Method of controlling proliferation and differentiation of stem and progenitor cells
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332219A2 Use of the human lrp/mvp promotor for a vector that can be induced by therapy
08/06/2003EP1332209A2 Collections of repeat proteins comprising repeat modules
08/06/2003EP1332206A1 Recombinant alpha-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
08/06/2003EP1331950A1 Methods and compositions for nucleic acid delivery
08/06/2003EP1331940A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
08/06/2003EP1098664B1 Conjugates for treating inflammatory disorders and associated tissue damage
08/06/2003EP1083934B1 EGR-1 for the manufacture of a medicament for treating wounds
08/06/2003EP0695305B1 Method of forming oligonucleotides
08/06/2003CN1434870A Viral core protein-cationic lipid-nucleic acid-delivery complexes
08/06/2003CN1434865A Regulation effect of conjugated frame transport protein ABC1
08/06/2003CN1434864A Method of enhancing immune responses to herpes simplex virus vaccine
08/06/2003CN1434862A Improvement of nucleic acid vaccination
08/06/2003CN1434831A Improvments in or relating to immune responses to HIV
08/06/2003CN1434727A Anglogenesis and vascular permeability modulators and inhibitors
08/06/2003CN1434726A Multivalent platform molecules comprising high molecular weight polyethylene oxide
08/06/2003CN1434718A Activation and inhibition of immune system
08/06/2003CN1434120A ST13 gene 5' terminal promotion function zone sequence and use thereof
08/06/2003CN1434054A Dowble-stranded RNA and use thereof
08/06/2003CN1117156C Non self-inactivating, expression targeted retroviral vectors
08/06/2003CN1117149C Compounds and methods for immunotherapy and diagnosis of tuberculosis
08/06/2003CN1117148C Vaccineforinfections agents, compositions for treating and preventing HIV infections
08/06/2003CN1117097C Cancer suppressor action of antisense nucteic acid of para-insulin growth factor receptor gene
08/05/2003US6603998 Delivery of macromolecules into cells
08/05/2003US6602984 Human elastase IV
08/05/2003US6602857 Antisense modulation of PTP1B expression
08/05/2003US6602713 Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
08/05/2003US6602709 Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
08/05/2003US6602707 Mammalian cell surface DNA receptor-encoding nucleic acid
08/05/2003US6602706 Cell comprising nucleotide sequence encoding viral gene product and recombinant nucleic acids lacking overlapping sequences; virus unable to replicate; use in treatment of genetic disorders and autoimmune diseases; antitumor agent
08/05/2003US6602705 Expression of HIV polypeptides and production of virus-like particles
08/05/2003US6602694 Of given amino acid sequence; can use to treat conditions in which the regulation of thermogenesis is desired (obesity, diabetes, malignant hyperthermia, and fever)
08/05/2003US6602686 Compositions and method for non-targeted activation of endogenous genes
08/05/2003US6602667 Of given sequence; useful for diagnosis, prognosis, treatment of inflammatory disorders; screening to identify ligands which bind the polynucleotides
08/05/2003US6602506 Immunogenic composition; bactericidal
08/05/2003US6602501 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
08/05/2003US6602499 Viral mutants for selectively killing neoplastic cells; herpes simplex virus vector; transgene encoding cytochrome P450, chemotherapeutic agent activated by cytochrome P450; viral mediated oncolysis and anticancer "suicide" gene therapy
08/05/2003CA2329259C Convection-enhanced delivery of aav vectors
08/05/2003CA2228590C Cerebellum-derived growth factors, and uses related thereto
07/2003
07/31/2003WO2003062472A1 Cooperative oligonucleotides
07/31/2003WO2003062469A2 Gene matn3 or matrilin-3 linked to osteoarthritis treatment
07/31/2003WO2003062447A2 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression
07/31/2003WO2003062435A1 A method for generating engineered cells for locus specific gene regulation and analysis
07/31/2003WO2003062424A1 Nucleic acid sequence comprising the rna packaging signal of a group 1 coronavirus and the applications thereof
07/31/2003WO2003062421A1 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
07/31/2003WO2003062414A2 Methods of obtaining isoform specific expression in mammalian cells
07/31/2003WO2003062394A2 Methods and compositions for rna interference
07/31/2003WO2003062390A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
07/31/2003WO2003062373A2 Methods and materials for the recruitment of endothelial cells
07/31/2003WO2003062372A2 Nanoparticle assembled hollow spheres
07/31/2003WO2003062278A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
07/31/2003WO2003062276A2 Multimers of receptor-binding ligands
07/31/2003WO2003062274A1 Novel proteins and dnas thereof
07/31/2003WO2003062273A2 Modulator of the notch signalling pathway and use thereof in medical treatment
07/31/2003WO2003062262A2 Modulation of heat-shock-protein-based immunotherapies
07/31/2003WO2003061710A1 AGENT CONTROLLING THE APOPTOSIS INDUCTION BY p73
07/31/2003WO2003061708A1 Stabilized formulations of adenovirus
07/31/2003WO2003061697A1 Preventives/remedies for cancer
07/31/2003WO2003061681A2 Proteins involved in the regulation of energy homeostasis and organelle metabolism
07/31/2003WO2003061629A2 Dna dosage forms
07/31/2003WO2003061591A2 Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
07/31/2003WO2003061587A2 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION
07/31/2003WO2003061582A2 Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
07/31/2003WO2003061580A2 Alteration of rab38 function to modulate mammalian pigmentation
07/31/2003WO2003061573A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
07/31/2003WO2003061564A2 Gene expression profiles in liver disease
07/31/2003WO2003061560A2 Replication competent dual-ad vectors for vaccine and immunotherapy applications
07/31/2003WO2003061551A2 Ex-vivo gene therapy of diabetes using iap polypeptides
07/31/2003WO2003040339A3 Antisense modulation of purinoreceptor p2x¿3?
07/31/2003WO2003037253A3 Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
07/31/2003WO2003035679A3 Molecules
07/31/2003WO2003030720A3 Materials and methods for preventing or reducing scar formation
07/31/2003WO2003028636A3 Antisense modulation of il-1 receptor-associated kinase-4 expression
07/31/2003WO2003027246A3 Antagonists
07/31/2003WO2003025140A3 Transductin-1 and transductin-2 and applications to hereditary deafness
07/31/2003WO2003016333A3 Virus coat protein/receptor chimeras and methods of use
07/31/2003WO2003010139A3 Antisense modulation of hormone-sensitive lipase expression
07/31/2003WO2003006607A3 Inhibition of apoptosis process and improvement of cell performance
07/31/2003WO2002101005A3 A g-protein coupled receptor and uses therefor
07/31/2003WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
07/31/2003WO2002099042A3 Cads as modifiers of the p53 pathway and methods of use
07/31/2003WO2002088363A3 Regulation of novel human prolyl 4-hydroxylases
07/31/2003WO2002086123A3 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
07/31/2003WO2002063000A3 Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same
07/31/2003WO2002059346A3 Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
07/31/2003WO2002059292A3 Functional balanced-lethal host-vector systems
07/31/2003WO2002047730A3 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
07/31/2003WO2002039885A3 Compositions and methods for the therapy and diagnosis of ovarian cancer
07/31/2003WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
07/31/2003WO2002024909A3 Receptor nucleic acids and polypeptides
07/31/2003WO2002024897A3 Conditionally replicating viral vectors and their use
07/31/2003WO2002024747A3 Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications
07/31/2003WO2002018548A3 Tyrosine hydroxylase 5' control elements and uses thereof
07/31/2003WO2002018444A3 Erbb4 antagonists
07/31/2003WO2002012286A3 Stress proteins and peptides and methods of use thereof
07/31/2003WO2001080902A8 A particulate complex for administering nucleic acid into a cell
1 ... 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 ... 870